Biopharmx Corp (NYSEAmerican:BPMX) reported that the USPTO has granted the first patent in what the firm anticipates will be a new family of patents safeguarding its unique topical gel delivery system that enables for greater bioavailability of an API.
The buzz
The patent covers a topical composition constituted of minocycline or another tetracycline-class medication and a process for developing such compositions. It also comprises treatments of dermatological infection or inflammation utilizing a minocycline composition. Existing formulations safeguarded by the patent comprise BPX-01 for the cure of acne and BPX-04 for the cure of rosacea.
This marks as the fourth U.S. patent release BioPharmX has obtained. Three earlier-given U.S. patents protect the firm’s encapsulation delivery setup, which can separate the API. The US 9,918,998 patent safeguards tetracycline-class offerings carried by company’s unique delivery system, which for the preliminary time stabilizes and entirely solubilizes these medications to make them workable in a topical formulation. This comprises items that utilize other tetracycline-class drugs and combination products.
Anja Krammer, the Co-Founder and President, expressed that this patent protection is a remarkable milestone for company. It recognizes that their advancement of a topical tetracycline-class drug is truly unique. And, like their other patents, it will protect their valuable intellectual property for a considerable length of time. It recognizes the unique R&D that BioPharmX has successfully done and ensures that their investors and company will benefit from it as they commercialize their products.
Oral minocycline has been extensively used since the 1970s, but oral antibiotics incline to flood the body with drug and are commonly related with harmful effects that range from diarrhea to nausea. Also, there is rising concern over the increase in antibiotic-resistant bacteria. BioPharmX marks as the first firm to advance a topical gel preparation of minocycline that reaches directed areas of the skin.
THE MORNING REPORT
Start your workday the right way with the news that matters most.
Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy
